Radiofrequency ablation in the management of primary hepatic and biliary tumors.

Document Type

Article

Publication Date

1-15-2022

Publication Title

World J Gastrointest Oncol

Keywords

washington; swedish; swedish dhi; swedish digestive health

Abstract

In the United States, 80%-90% of primary hepatic tumors are hepatocellular carcinomas and 10%-15% are cholangiocarcinomas (CCA), both with high mortality rate, particularly CCA, which portends a worse prognosis. Traditional management with surgery has good outcomes in appropriately selected patients; however, novel ablative treatment options have emerged, such as radiofrequency ablation (RFA), which can improve the prognosis of both hepatic and biliary tumors. RFA is aimed to generate an area of necrosis within the targeted tissue by applying thermal therapy via an electrode, with a goal to completely eradicate the tumor while preserving surrounding healthy tissue. Role of RFA in management of hepatic and biliary tumors forms the focus of our current mini-review article.

Keywords: Biliary tumor; Cholangiocarcinoma; Cholangiocarcinomas; Hepatic tumor; Hepatocellular carcinoma; Hepatocellular carcinomas; Radiofrequency ablation

Clinical Institute

Digestive Health

Clinical Institute

Kidney & Diabetes

Clinical Institute

Cancer

Department

Gastroenterology

Department

Endocrinology

Department

Oncology

Link to Full Text

PSJH Full Text

Share

COinS